Novel Therapies for Inflammation Resolution
Developing a pipeline of therapies for solid tumor cancers and autoimmune diseases.
Our lead program TP-317 is a first-in-class new molecular entity (NME) that delivers Resolvin E1 (RvE1), an eicosanoid that resolves inflammation without compromising host defense. RvE1 is a ligand for ChemR23, a G-protein coupled receptor (GPCR) that is resident on macrophages and other immune cells.
In multiple models of disease, RvE1 has been shown to address key aspects of disease pathophysiology, including downregulation of inflammatory mediators and cytokines (NF-κB, TNF-α, IL-12, IL-6, IL-1β, IFN-γ), increased macrophage-induced uptake of apoptotic cells via phagocytosis/efferocytosis, reduced neutrophil migration, and increased neutrophil apoptosis and tissue repair. Taken together, these pro-resolving properties make TP-317 an attractive, non-immunosuppressive candidate for the treatment of cancer and inflammatory bowel disease (IBD).
Based on Phase 1 clinical trials demonstrating the favorable safety and tolerability of orally administered RvE1 in healthy volunteers, Thetis plans to advance TP-317 rapidly into clinical development.
Beyond TP-317, Thetis’ technology platform enables the development of additional Resolvins in various diseases. In addition, Thetis has a collaboration with NIH to leverage the HEALER platform in inflammatory liver diseases.
For partnering inquiries, please email email@example.com.